ArticleTransplant infectious disease : an official journal of the Transplantation Society
Effects of Various Immunoglobulin Products on Serum (1-3)-β-D-glucan Levels.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background(1-3)-β-D-glucan (β-D-glucan), a component of fungal cell walls and an important diagnostic biomarker of invasive fungal infections, is affected by various factors, particularly in allogeneic hematopoietic cell transplantation (allo-HCT) recipients. Patients receiving allo-HCT also receive immunoglobulin replacement therapy (IgRT); however, little is known about the effects of different types of immunoglobulin products on serum β-D-glucans. Here, we examined the levels of serum β-D-glucan following IgRT, as well as the correlation between changes in serum β-D-glucan and IgG levels.
methodsSerum β-D-glucan levels in patients who underwent allo-HCT and IgRT at our institution between 2021 and 2024 were analyzed retrospectively. Patients who had their serum β-D-glucan measured within 7 days before and after IgRT were included, and changes in serum β-D-glucan levels were evaluated across product types. Finally, the magnitude of these changes was assessed using effect sizes.
resultsA total of 125 administrations of three types of immunoglobulin product (Privegen [n = 63], Venoglobulin [n = 38], and Venilon-I [n = 24]) were examined. The median dose of immunoglobulin was 538.9 (57.4-700.9) mg/kg. We noted a significant increase in serum β-D-glucan levels after administration of Privigen, with a large effect size (Cohen's dz = 0.92; 95% confidence interval 0.48-1.35, p < 0.01). No meaningful changes were detected with Venoglobulin or Venilon-I. Elevated serum β-D-glucan levels returned to baseline within approximately 3 weeks of Privigen administration. Multivariable analysis indicated that Privigen was an independent factor associated with higher serum β-D-glucan levels.
conclusionDifferent immunoglobulin products have different effects on serum β-D-glucan levels after IgRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.